Adela, Foster City, CA, Onsite
Adela’s mission is to deliver innovative and accessible blood tests that harness biology to transform cancer care and improve well-being. The company is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela’s blood-based, tissue-free product ensures universal accessibility to MRD testing for patients with cancer, eliminating any dependency on tumor tissue availability. Adela’s first product was recently clinically validated for predicting and surveilling for recurrence in patients with head & neck cancer and published in Annals of Oncology.
Adela is seeking aClinical Laboratory Scientist III to join our Commercial team.This is an opportunity to partner with the Director of Clinical Lab Operations and Assay Development to transfer technology, develop assays and support clinical sample processing in the CLIA/CAP accredited laboratory
The annual base salary range for this position $140,000 to $155,000 USD. This range reflects only the base salary component of compensation and is provided in compliance with applicable pay transparency requirements. Actual base salary will be determined at the Company’s discretion and may vary based on a number of factors, including but not limited to geographic location, relevant experience, skills, qualifications, internal equity, and business needs.
Adela is an equal opportunity employer committed to fostering a diverse and inclusive workplace. We provide equal employment opportunities to all employees and applicants and prohibit discrimination and harassment of any kind, in accordance with applicable laws in the United States and Canada.
Employment decisions are made without regard to any characteristic protected by applicable federal, state, provincial, or local laws, including race, color, religion or creed, sex (including pregnancy), sexual orientation, gender identity or expression, national origin or ancestry, age, disability, genetic information, marital or family status, or veteran or military status.
We are committed to providing reasonable accommodations in accordance with applicable laws.
Adela’s mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. Adela’s genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network’s Princess Margaret Cancer Centre. Adela is initially planning to develop the technology for use across the entire cancer continuum—for detection, diagnosis and management of disease.
View company profile →